ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2366

High Uric Acid As a Risk Factor for Cardiovascular Diseases in Rheumatoid Arthritis Patients

Adeeba Al-Herz1, Ali Aldei1, Khulood Saleh2, Adel Al-Awadhi3, Waleed Al-Kandari2, Eman Hasan4, Aqeel Ghanem5, Mohammad Hussain4, Ibrahim Nahar5, Fatemah Abutiban6, Ahmad Alenizi6, Yaser Ali5, Hebah Alhajeri5, Sawsan Hayat5, Ahmad Khadrawy2, Ammad Fazal2, Khaled Mokaddem1, Agaz Zaman5, Ghada Mazloum5, Youssef Bartella1, Sally Hamed1, Ramia Alsouk6 and Ahmed Al-Saber7, 1Rheumatology, Al-Amiri Hospital, Kuwait city, Kuwait, 2Rheumatology, Farwania Hospital, Farwania, Kuwait, 3Faculty of Medicine, Kuwait, Kuwait, 4Al-Amiri Hospital, Kuwait city, Kuwait, 5Rheumatology, Mubarak Al-Kabeer Hospital, Hawally, Kuwait, 6Rheumatology, Jahra Hospital, Jahra, Kuwait, 7Department of Mathematics, Kuwait Technical College, Kuwait city, Kuwait

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Cardiovascular disease, Co-morbidities, registry, rheumatoid arthritis (RA) and uric acid

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) patients have an increased risk of cardiovascular diseases (CVD). It is unclear whether an elevated serum uric acid (UA) further increases that risk. We study CVD and their risk factors in association with UA in RA patients.

Methods: Adult patients who satisfied the ACR classification criteria for RA from The Kuwait Registry for Rheumatic Diseases (KRRD) from four major hospitals were evaluated from February 2013 through May 2017. Patients with recorded UA were identified and CVD and their risk factors were studied in those patients. To optimize classifier number and prediction accuracy, hierarchical cluster analyses for multiple factors were performed, which indicated nine possible independent CVD risk factors. A binary logistic regression was conducted to examine their significant association with CVD and the independence of UA as a risk factor.

Results: A total of 564 RA patients with available UA were identified, 353(62.6%) females. Mean age was 50.8+11.5 years and disease duration 10.5+2.9 years.

Mean UA was 271+78µmol/L. Of those patients, 31 (5.5%) were reported to have CVD. UA was significantly correlated to the presence of CVD (χ2=6.49, p=0.011). Logistic regression model indicated a 10% increase of CVD with every 10 µmol/L increase in UA (table). A correlation matrix between UA and other risk factors showed a significant association between high uric acid and a younger age at RA diagnosis (r=-0.262), hyperlipidemia (r=0.191) and diabetes mellitus (r=0.244).

B

p-value

Odds Ratio

95% C.I.

Lower

Upper

Uric acid

0.011

<0.001*

1.011

1.006

1.016

Smoking

-0.535

0.280

0.586

0.222

1.546

Anti-cyclic citrullinated peptide antibodies

-1.017

0.115

0.362

0.102

1.280

Rheumatoid factor

-0.717

0.337

0.488

0.113

2.111

Age at RA diagnosis

-0.071**

<0.001*

0.931

0.896

0.968

Hyperlipidemia

2.220

0.001*

9.210

2.606

32.548

Hypertension

1.824

<0.001*

6.199

2.470

15.556

Male gender

-1.097**

0.020*

0.334

0.132

0.844

Diabetes mellitus

2.619

<0.001*

13.724

4.665

40.372

Conclusion: Our study suggests that UA may be an independent risk factor for CVD and is associated with the presence of other risk factors. UA should be measured and carefully approached in RA patients.


Disclosure: A. Al-Herz, None; A. Aldei, None; K. Saleh, None; A. Al-Awadhi, None; W. Al-Kandari, None; E. Hasan, None; A. Ghanem, None; M. Hussain, None; I. Nahar, None; F. Abutiban, None; A. Alenizi, None; Y. Ali, None; H. Alhajeri, None; S. Hayat, None; A. Khadrawy, None; A. Fazal, None; K. Mokaddem, None; A. Zaman, None; G. Mazloum, None; Y. Bartella, None; S. Hamed, None; R. Alsouk, None; A. Al-Saber, None.

To cite this abstract in AMA style:

Al-Herz A, Aldei A, Saleh K, Al-Awadhi A, Al-Kandari W, Hasan E, Ghanem A, Hussain M, Nahar I, Abutiban F, Alenizi A, Ali Y, Alhajeri H, Hayat S, Khadrawy A, Fazal A, Mokaddem K, Zaman A, Mazloum G, Bartella Y, Hamed S, Alsouk R, Al-Saber A. High Uric Acid As a Risk Factor for Cardiovascular Diseases in Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/high-uric-acid-as-a-risk-factor-for-cardiovascular-diseases-in-rheumatoid-arthritis-patients/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-uric-acid-as-a-risk-factor-for-cardiovascular-diseases-in-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology